• Study of 329 Patients in Europe Shows Superior Performance Compared to Microscopic Diagnosis
  • Sensitivity: 94.4%, Specificity: 97.2%, Agreement Rate: 92%
YONGIN, South Korea, Sept. 24, 2024 /PRNewswire/ -- Noul Co., Ltd. (CEO: David Lim, hereafter referred to as "Noul") has proven the expert-level diagnostic performance of its AI in Europe. Noul presented the AI diagnostic performance results of miLab at the 2024 International Congress for Tropical Medicine and Malaria. The study, conducted by National Center for Microbiology of Carlos III Health Institute in Spain, showed a sensitivity of 94.4%, specificity of 97.2%, and a concordance of 92% compared to microscopic diagnosis.

Noul Demonstrates 'Expert-Level' AI Diagnostic Performance in Europe… Results from Spain's Carlos III Health Institute

Register to unlock this article

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here